79 related articles for article (PubMed ID: 19862681)
1. Pharmacokinetics, bioavailability and effects on electrocardiographic parameters of oral fludarabine phosphate.
Yin W; Karyagina EV; Lundberg AS; Greenblatt DJ; Lister-James J
Biopharm Drug Dispos; 2010 Jan; 31(1):72-81. PubMed ID: 19862681
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia.
Foran JM; Oscier D; Orchard J; Johnson SA; Tighe M; Cullen MH; de Takats PG; Kraus C; Klein M; Lister TA
J Clin Oncol; 1999 May; 17(5):1574-9. PubMed ID: 10334546
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate.
Malspeis L; Grever MR; Staubus AE; Young D
Semin Oncol; 1990 Oct; 17(5 Suppl 8):18-32. PubMed ID: 1699279
[TBL] [Abstract][Full Text] [Related]
4. Dialysate concentration and pharmacokinetics of 2F-Ara-A in a patient with acute renal failure.
Kielstein JT; Stadler M; Czock D; Keller F; Hertenstein B; Radermacher J
Eur J Haematol; 2005 Jun; 74(6):533-4. PubMed ID: 15876260
[TBL] [Abstract][Full Text] [Related]
5. The bioavailability of oral fludarabine phosphate is unaffected by food.
Oscier D; Orchard JA; Culligan D; Cunningham D; Johnson S; Parker A; Klein M; Gieschen H
Hematol J; 2001; 2(5):316-21. PubMed ID: 11920267
[TBL] [Abstract][Full Text] [Related]
6. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia.
Gandhi V; Kemena A; Keating MJ; Plunkett W
Cancer Res; 1992 Feb; 52(4):897-903. PubMed ID: 1737352
[TBL] [Abstract][Full Text] [Related]
7. Cellular and clinical pharmacology of fludarabine.
Gandhi V; Plunkett W
Clin Pharmacokinet; 2002; 41(2):93-103. PubMed ID: 11888330
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia.
Rossi JF; van Hoof A; de Boeck K; Johnson SA; Bron D; Foussard C; Lister TA; Berthou C; Kramer MH; Littlewood TJ; Marcus RE; Deconinck E; Montillo M; Guibon O; Tollerfield SM
J Clin Oncol; 2004 Apr; 22(7):1260-7. PubMed ID: 15051774
[TBL] [Abstract][Full Text] [Related]
9. In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis.
Kano Y; Akutsu M; Tsunoda S; Suzuki K; Ichikawa A; Furukawa Y; Bai L; Kon K
Leukemia; 2000 Mar; 14(3):379-88. PubMed ID: 10720130
[TBL] [Abstract][Full Text] [Related]
10. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
[TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: a prospective dose adjustment study.
Lichtman SM; Etcubanas E; Budman DR; Eisenberg P; Zervos G; D'Amico P; O'Mara V; Musgrave K; Cascella P; Melikian A; Hinderling PH; Ferrer JM; Williams GJ
Cancer Invest; 2002; 20(7-8):904-13. PubMed ID: 12449721
[TBL] [Abstract][Full Text] [Related]
12. High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation.
Long-Boyle JR; Green KG; Brunstein CG; Cao Q; Rogosheske J; Weisdorf DJ; Miller JS; Wagner JE; McGlave PB; Jacobson PA
Bone Marrow Transplant; 2011 Jan; 46(1):20-6. PubMed ID: 20383215
[TBL] [Abstract][Full Text] [Related]
13. Encapsulation, metabolism and release of 2-fluoro-ara-AMP from human erythrocytes.
Fraternale A; Rossi L; Magnani M
Biochim Biophys Acta; 1996 Oct; 1291(2):149-54. PubMed ID: 8898876
[TBL] [Abstract][Full Text] [Related]
14. Estimating mass balance for inhaled drugs in humans: an example with a VLA-4 antagonist, IVL745.
Rohatagi S; Shah B; Zhang J; Zeng Z; Kirkesseli S; Jensen BK
J Clin Pharmacol; 2004 Apr; 44(4):348-58. PubMed ID: 15051741
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of nelarabine in indolent leukemias.
Gandhi V; Tam C; O'Brien S; Jewell RC; Rodriguez CO; Lerner S; Plunkett W; Keating MJ
J Clin Oncol; 2008 Mar; 26(7):1098-105. PubMed ID: 18309944
[TBL] [Abstract][Full Text] [Related]
16. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
Avramis IA; Laug WE; Sausville EA; Avramis VI
Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
[TBL] [Abstract][Full Text] [Related]
17. Incorporation of fludarabine and 1-beta-D-arabinofuranosylcytosine 5'-triphosphates by DNA polymerase alpha: affinity, interaction, and consequences.
Gandhi V; Huang P; Chapman AJ; Chen F; Plunkett W
Clin Cancer Res; 1997 Aug; 3(8):1347-55. PubMed ID: 9815818
[TBL] [Abstract][Full Text] [Related]
18. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of Ara-CMP-Stearate (YNK01): phase I study of the oral Ara-C derivative.
Schleyer E; Braess J; Ramsauer B; Unterhalt M; Kaufmann C; Wilde S; Schüssler M; Hiddemann W
Leukemia; 1995 Jun; 9(6):1085-90. PubMed ID: 7596174
[TBL] [Abstract][Full Text] [Related]
20. Retrospective analysis of electrocardiographic changes after administration of oral or intravenous garenoxacin in five phase I, placebo-controlled studies in healthy volunteers.
Wang Z; Grasela DM; Krishna G
Clin Ther; 2007 Jun; 29(6):1098-106. PubMed ID: 17692724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
